Search Result

Isoforms Recommended:	CXCR2

Results for "

CXCR2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CXCR (67) Apoptosis (2) Arrestin (1) Autophagy (1) CCR (4) CX3CR1 (1) Drug Metabolite (3) Endogenous Metabolite (3) Fluorescent Dye (1) Fungal (2) HIV (1) HSV (1) IFNAR (1) Interleukin Related (6) Isotope-Labeled Compounds (1) mRNA (1) NOD-like Receptor (NLR) (1) Oxidative Phosphorylation (2) Protein Arginine Deiminase (1) Reactive Oxygen Species (ROS) (1) Reference Standards (8) Small Interfering RNA (siRNA) (3) TNF Receptor (1)
By Research Areas:	Cancer (27) Endocrinology (23) Infection (5) Inflammation/Immunology (52) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Chemokine & Receptors (1) Rat Pre-designed siRNA Sets (1) mRNA (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: CXCR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16711

SB225002 55+ Cited Publications	CXCR	Inflammation/Immunology Endocrinology Cancer
SB225002, a potent, selective and non-peptide *CXCR2* antagonist, inhibits ¹²⁵I-IL-8 binding to CXCR2 with an IC₅₀ of 22 nM.

HY-19855

AZD-5069 10+ Cited Publications	CXCR	Endocrinology Cancer
AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.

HY-15251

Reparixin Maximum Cited Publications 62 Publications Verification Repertaxin; DF 1681Y	CXCR	Inflammation/Immunology Endocrinology Cancer
Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors *CXCR1* and *CXCR2* activation with IC₅₀s of 1 and 100 nM, respectively.

HY-13848

Rugocrixan 20+ Cited Publications AZD8797; KAND567	CX3CR1 CXCR	Inflammation/Immunology Endocrinology Cancer
AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with K_is of 3.9 and 2800 nM, respectively .

HY-10198

Navarixin 30+ Cited Publications SCH 527123; MK-7123	CXCR	Inflammation/Immunology Endocrinology Cancer
Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both *CXCR1* and *CXCR2, with K_d* values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly ^[2].

HY-119339

SX-682 5+ Cited Publications	CXCR	Inflammation/Immunology Endocrinology Cancer
SX-682 is an orally bioavailable, potent allosteric inhibitor of *CXCR1* and *CXCR2*. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity .

HY-101407

Nicotinamide N-oxide 3 Publications Verification	Oxidative Phosphorylation CXCR Drug Metabolite Endogenous Metabolite	Inflammation/Immunology Endocrinology
Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the *CXCR2* receptor.

HY-50688

SB-265610 5+ Cited Publications	CXCR	Inflammation/Immunology
SB-265610 is a selective, competitive, nonpeptide and allosteric *CXCR2* antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC₅₀s of 3.7 nM and 70 nM, respectively ^[2].

HY-101022

CXCR2-IN-1 4 Publications Verification	CXCR	Inflammation/Immunology Endocrinology
CXCR2-IN-1 is a central nervous system penetrant *CXCR2* antagonist with a pIC₅₀ of 9.3.

HY-120878

CXCR2-IN-2 1 Publications Verification	CXCR	Inflammation/Immunology
CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable *CXCR2* antagonist (IC₅₀=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively). CXCR2-IN-2 displays ~730-fold selectivity over CXCR1 and >1900-fold selectivity over all other chemokine receptors. CXCR2-IN-2 inhibits human whole blood Gro-α induced CD11b expression with an IC₅₀ of 0.04 μM .

HY-19768

Danirixin 5+ Cited Publications GSK1325756	CXCR	Inflammation/Immunology Endocrinology
Danirixin is a selective, and reversible *CXCR2* antagonist, with IC₅₀?of?12.5 nM for CXCL8.

HY-19519A

Ladarixin sodium 1 Publications Verification DF 2156A	CXCR	Infection Inflammation/Immunology Cancer
Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual *CXCR1* and *CXCR2* antagonist. Ladarixin sodium can be used for the research of COPD and asthma .

HY-19519

Ladarixin 1 Publications Verification DF 2156A free base	CXCR	Inflammation/Immunology Cancer
Ladarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual *CXCR1* and *CXCR2* antagonist. Ladarixin can be used for the research of COPD and asthma .

HY-120427

Cosalane 1 Publications Verification NSC 658586	CCR CXCR HIV HSV	Infection Inflammation/Immunology
Cosalane (NSC 658586) is a CCR7 (IC₅₀ = 2.43 μM) and *CXCR2* antagonist (IC₅₀ = 0.66 μM). Cosalane is an inhibitor of HIV replication with a wide range of activity against HIV-1 isolates, HIV-2, Rauscher murine leukemia virus, HSV-1, *HSV-2* and human cytomegalovirus. Cosalane inhibits both attachment of gp120 to CD4. Cosalane inhibits human and murine CCR7 in response to both CCL19 and CCL21 agonists. Cosalane can be studied in research for HIV or attenuating acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (HSCT) ^[2] .

HY-153450

JBI-589	Protein Arginine Deiminase	Cancer
JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research ^[2].

HY-165428

SCH-900875	CXCR Arrestin	Inflammation/Immunology
SCH-900875 is an orally active, brain-penetrant and selective CXCR3 receptor inhibitor, which also shows high selectivity over *CXCR1* and CXCR2 receptors. SCH-900875 binds to CXCR3, blocking the binding of ligands CXCL9, CXCL10, and CXCL11, inhibiting downstream G protein and β-arrestin signaling pathways to suppress inflammatory cell migration. SCH-900875 is promising for research of autoimmune diseases (rheumatoid arthritis, multiple sclerosis) and inflammatory disorders (psoriasis, inflammatory bowel disease) ^[2].

HY-145640

Vimnerixin AZD4721; RIST4721	CXCR	Inflammation/Immunology
Vimnerixin (AZD4721) is the potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2). Vimnerixin has the potential for the research of inflammatory disease .

HY-147392

CXCR2 antagonist 8	CXCR	Metabolic Disease
CXCR2 antagonist 8 is a potent and selective *CXCR2* antagonist. CXCR2 antagonist 8 can be used for insulin resistance research .

HY-15462

SRT3109 2 Publications Verification AZD-5122	CXCR	Inflammation/Immunology Endocrinology
SRT3109 is an antagonist of *CXCR2, with a pIC₅₀* of 8.2, and used in the research of chemokine mediated diseases.

HY-10011

SCH 563705 4 Publications Verification	CXCR	Inflammation/Immunology Endocrinology
SCH 563705 is a potent and orally available *CXCR2* and *CXCR1* antagonist, with IC₅₀s of 1.3 nM, 7.3 nM and K_is of 1 and 3 nM, respectively.

HY-119259

AZD8309	CXCR	Inflammation/Immunology
AZD8309 is an orally active antagonist of *CXCR2*. AZD8309 has the ability to regulate the transmigration of neutrophils. AZD8309 can be used in the study of inflammatory diseases .

HY-12927

SX-517	CXCR	Inflammation/Immunology
SX-517 is a dual *CXCR2/1* antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca ²⁺ flux (IC₅₀=38 nM), and antagonizes CXCL8-induced [(35)S]GTPγS binding (IC₅₀=60 nM) and *ERK1/2* phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model ^[2].

HY-139873

CXCR2 antagonist 2	CXCR	Cancer
CXCR2 antagonist 2 is a potent *CXCR2* antagonist for cancer immunoresearch with an IC₅₀ value of 95 nM.

HY-18263C

Elubrixin tosylate SB-656933 tosylate	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active *CXCR2* antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation ^[2] .

HY-16981

SB-332235	CXCR	Inflammation/Immunology
SB-332235 is a potent, orally active nonpeptide *CXCR2* antagonist, with an IC₅₀ of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells ^[2].

HY-P4846

Ac-Pro-Gly-Pro-OH 2 Publications Verification	CXCR Apoptosis IFNAR TNF Receptor Interleukin Related	Infection Inflammation/Immunology
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a *CXCR2* agonist . Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer ^[2] .

HY-RS03400

CXCR2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CXCR	Others
CXCR2 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR2 Human Pre-designed siRNA Set A CXCR2 Human Pre-designed siRNA Set A

HY-15251A

(Rac)-Reparixin (Rac)-Repertaxin; (Rac)-DF 1681Y	CXCR	Inflammation/Immunology Endocrinology Cancer
(Rac)-Reparixin is the isomer of Reparixin (HY-15251), and can be used as an experimental control. Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors *CXCR1* and *CXCR2* activation with IC₅₀s of 1 and 100 nM, respectively.

HY-149096

CCR7 antagonist 1	CXCR	Others
CCR7 antagonist 1 (30c) is a dual *CXCR2* (IC₅₀ of 11.02 μM) and CCR7 (IC₅₀ of 0.43 μM) antagonist .

HY-179387

CXCR2-IN-3	CXCR Autophagy NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) Apoptosis	Cancer
CXCR2-IN-3 is a *CXCR2* inhibitor with an IC₅₀ of 11.37 μM. CXCR2-IN-3 mediates CXCR2-Ca ²⁺ signalling inhibition halted autophagic flux, subsequently facilitating ROS-mediated apoptotic cell death. CXCR2-IN-3 suppresses the CXCR2-NLRP3 canonical pathway, suppressing pre-tumorigenic markers. CXCR2-IN-3 causes autophagy-dependent cell death in polyploid giant cancer cells (PGCCs). CXCR2-IN-3 can be used for the research of oral squamous cell carcinoma (OSCC) .

HY-139874

CXCR2 antagonist 3	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 3 (compound 11h) is a potent antagonist of CXC chemokine receptor 2 (CXCR2). CXCR2 antagonist 3 demonstrates double-digit nanomolar potencies against CXCR2 and significantly inhibited neutrophil infiltration into the air pouch. CXCR2 antagonist 3 reduces the infiltration of neutrophils and MDSCs and enhance the infiltration of CD3 ⁺ T lymphocytes into the Pan02 tumor tissues .

HY-13021

SRT3190	CXCR	Inflammation/Immunology Endocrinology
SRT3190 is an antagonist of *CXCR2*, used in the research of chemokine mediated diseases.

HY-N2573

Corydalmine L-Corydalmine; TLZ-16	Fungal CXCR	Infection Neurological Disease
Corydalmine (L-Corydalmine) inhibits spore germination of some plant pathogenic as well as saprophytic fungi . Corydalmine acts as an oral analgesic agent, exhibiting potent analgesic activity ^[2]. Corydalmine alleviates Vincristine-induced neuropathic pain in mice by inhibiting an NF-κB-dependent CXCL1/CXCR2 signaling pathway .

HY-163475

*CXCL-CXCR1/2-IN-1* 1 Publications Verification	CXCR	Cancer
CXCL-CXCR1/2-IN-1 is an orally active ELR ⁺CXCL-CXCR1/2 pathway inhibitor with an EC₅₀ of 42.7 nM for CXCR2 . CXCL-CXCR1/2-IN-1 shows anticancer and antiangiogenic effects .

HY-144784

CXCR2 antagonist 7	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 7 (compound 19) is a potent *CXCR2* antagonist. CXCR2 antagonist 7 shows potent *CXCR2* binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-144781

CXCR2 antagonist 5	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 5 (compound 25) is a potent *CXCR2* antagonist. CXCR2 antagonist 5 shows potent *CXCR2* binding affinity (IC₅₀=0.013 µM) and calcium mobilization (IC₅₀=0.1 µM) ^{[ 1]}.

HY-144783

CXCR2 antagonist 6	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 6 (compound 35c) is a potent *CXCR2* antagonist. CXCR2 antagonist 6 shows potent *CXCR2* binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-144780

CXCR2 antagonist 4	CXCR	Cancer
CXCR2 antagonist 4 (compound 7) is a potent *CXCR2* antagonist with an IC₅₀ value of 0.13 μM. CXCR2 antagonist 4 can inhibit CXCL8-induced cytosolic calcium increase (IC₅₀ = 27 μM). CXCR2 antagonist 4 can be used for researching anticancer .

HY-D2310

CXCR2 Probe 1	CXCR	Inflammation/Immunology
CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for *CXCR2* and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

HY-174727

*Human CXCR2* mRNA**	mRNA	Inflammation/Immunology
Human CXCR2 mRNA encodes the human C-X-C motif chemokine receptor 2 (CXCR2) protein, a member of the G-protein-coupled receptor family. CXCR2 is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 (CXCL1/MGSA), a protein with melanoma growth stimulating activity, and has been shown to be a major component required for serum-dependent melanoma cell growth.

HY-18263A

Elubrixin SB-656933	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active *CXCR2* antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation ^[2] .

HY-RS03401

Cxcr2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CXCR	Others
Cxcr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr2 Mouse Pre-designed siRNA Set A Cxcr2 Mouse Pre-designed siRNA Set A

HY-RS03402

Cxcr2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CXCR	Others
Cxcr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr2 Rat Pre-designed siRNA Set A Cxcr2 Rat Pre-designed siRNA Set A

HY-120878A

*(R,R)-CXCR2-IN-2*	CXCR	Neurological Disease Inflammation/Immunology Cancer
(R,R)-CXCR2-IN-2 (compound 67), diastereoisomer of CXCR2-IN-2 (compound 68) (HY-120878), is a *CXCR2* antagonist with a pIC₅₀ of 9 and 6.8 in the Tango assay and d in the HWB Gro-α induced CD11b expression assay, respectively .

HY-124056

AZ10397767	CXCR	Cancer
AZ10397767 is an orally active, selective CXCR2 receptor antagonist with an IC₅₀ of 1 nM. AZ10397767 attenuates the Oxaliplatin (HY-17371)-induced NF-κB transcriptional activity and potentiates Oxaliplatin-induced apoptosis in androgen-independent prostate cancer (AIPC) cells. AZ10397767 significantly inhibits neutrophil recruitment into tumors which then adversely affects tumor growth in vitro and in vivo ^[2] .

HY-110268

*NVP CXCR2* 20**	CXCR	Inflammation/Immunology
NVP CXCR2 20 is a selective *CXCR2* inhibitor with analgesic and antinociceptive activities. NVP CXCR2 20 selectively blocks CXCR2 signaling and attenuates mechanical and thermal hypersensitivity in rat chronic constriction injury (CCI) models. NVP CXCR2 20 inhibits CXCL3-induced hypersensitivity in naive mice and reduces elevated CXCL3 protein levels in the spinal cord and dorsal root ganglia (DRG) of CCI-exposed rats. NVP CXCR2 20 can be used for the research of neuropathic pain and chronic obstructive pulmonary disease (COPD) ^[2] .

HY-181681

CXCR2 antagonist 10	CCR CXCR	Cancer
CXCR2 antagonist 10 (Compound 10b) is a *CCR2* antagonist with an IC₅₀ of 0.48 μM. CXCR2 antagonist 10 also exhibits antagonistic activity against *CXCR2/CCR7*, with IC₅₀ values of 4.18 μM and 2.07 μM, respectively. CXCR2 antagonist 10 is applicable for cancer research .

HY-173491

CXCR2/CCR7 antagonist-1	CXCR CCR	Inflammation/Immunology Cancer
CXCR2/CCR7 antagonist-1 (compound 6) is a potent *CXCR2* and CCR7 dual antagonist with IC₅₀s of 0.0046 and 0.0014 μM, respectively. CXCR2/CCR7 antagonist-1 can be used in the study of cancer metastasis and autoimmune diseases .

HY-P991746

*Anti-Mouse CXCR2* Antibody (Cx2Mab-1)**	CXCR	Cancer
Anti-Mouse CXCR2 Antibody (Cx2Mab-1) reacts with mouse *CXCR2* targeting the N-terminal extracellular domain of CXCR2. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-101407R

Nicotinamide N-oxide (Standard)	Reference Standards CXCR Drug Metabolite Endogenous Metabolite	Inflammation/Immunology Endocrinology
Nicotinamide N-oxide (Standard) is the analytical standard of Nicotinamide N-oxide. This product is intended for research and analytical applications. Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the *CXCR2* receptor.

Cat. No.	Product Name	Target	Research Area

HY-P4846

Ac-Pro-Gly-Pro-OH 2 Publications Verification	CXCR Apoptosis IFNAR TNF Receptor Interleukin Related	Infection Inflammation/Immunology
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a *CXCR2* agonist . Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer ^[2] .

HY-125567

Antileukinate	CXCR	Inflammation/Immunology
Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury ^[2] .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991746

*Anti-Mouse CXCR2* Antibody (Cx2Mab-1)**	CXCR	Cancer
Anti-Mouse CXCR2 Antibody (Cx2Mab-1) reacts with mouse *CXCR2* targeting the N-terminal extracellular domain of CXCR2. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-P992036

*Anti-CXCR2* Antibody**	CXCR	Inflammation/Immunology
Anti-CXCR2 Antibody is an anti-CXCR2 antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P992035

AMY109	Interleukin Related	Endocrinology
AMY109 is an anti-human interleukin-8 (IL-8) monoclonal antibody, with IC₅₀ values of 0.14 μg/mL and 0.37 μg/mL against human IL-8, a K_a of 36.8 pM for human IL-8, and a K_a of 380 pM for cynomolgus monkey IL-8.\nAMY109 binds to human and cynomolgus monkey IL-8 in a pH-dependent manner, inhibits IL-8-mediated activation of *CXCR1* and *CXCR2*, and blocks the downstream biological activities of IL-8. AMY109 inhibits neutrophil recruitment to endometriotic lesions and suppresses monocyte chemoattractant protein-1 production by neutrophils. AMY109 is applicable to research related to endometriosis .

HY-P992014

*Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5)*	CXCR	Inflammation/Immunology
Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) is an antibody targeting *CXCR3, which specifically binds to an epitope within amino acid residues 23 to 44 of human CXCR3* .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-101407

Nicotinamide N-oxide 3 Publications Verification	Alkaloids Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Oxidative Phosphorylation CXCR Drug Metabolite Endogenous Metabolite
Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the *CXCR2* receptor.

HY-N2573

Corydalmine L-Corydalmine; TLZ-16	Alkaloids Monophenols Corydalis yanhusuo W. T. Wang Phenols Plants Isoquinoline Alkaloids Papaveraceae Source Classification	Fungal CXCR
Corydalmine (L-Corydalmine) inhibits spore germination of some plant pathogenic as well as saprophytic fungi . Corydalmine acts as an oral analgesic agent, exhibiting potent analgesic activity ^[2]. Corydalmine alleviates Vincristine-induced neuropathic pain in mice by inhibiting an NF-κB-dependent CXCL1/CXCR2 signaling pathway .

HY-101407R

Nicotinamide N-oxide (Standard)	Alkaloids Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Reference Standards CXCR Drug Metabolite Endogenous Metabolite
Nicotinamide N-oxide (Standard) is the analytical standard of Nicotinamide N-oxide. This product is intended for research and analytical applications. Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the *CXCR2* receptor.

Recombinant Proteins Recommended:

CXCR2

Species:	Human (2) Mouse (1)
Tag:	SUMO (1) His (3)
Source:	E. coli Cell-free (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P790083

	CXCR2 Protein, Human (Cell-Free, His) CXC-R2; CXCR-2; GRO/MGSA receptor; High affinity interleukin-8 receptor B (IL-8R B); IL-8 receptor type 2; CXCR2; IL8RB	Human	E. coli Cell-free
	CXCR2, the receptor for interleukin-8 (IL-8), orchestrates neutrophil activation through a G-protein-mediated phosphatidylinositol-calcium second messenger system upon IL-8 binding. Exhibiting high-affinity binding to IL-8, CXCR2 also interacts with other ligands like CXCL3, GRO/MGSA, and NAP-2. The involvement of GNAI2 underscores the intricate signaling mechanisms regulating neutrophil function through CXCR2. CXCR2 Protein, Human (Cell-Free, His) is the recombinant human-derived CXCR2, expressed by E. coli Cell-free, with N-10His labeled tag. The total length of CXCR2 Protein, Human (Cell-Free, His) is 360 a.a.*.

HY-P702257

	CXCR2 Protein, Mouse (Cell-Free, His) C-X-C chemokine receptor type 2; GRO/MGSA receptor; High affinity interleukin-8 receptor B; IL-8R B; CD182	Mouse	E. coli Cell-free
	CXCR2 protein acts as a receptor for interleukin-8 and induces neutrophil activation through the G protein-mediated phosphatidylinositol-calcium second messenger system. In addition to IL-8, CXCR2 also exhibits high-affinity binding to ligands such as CXCL3, GRO/MGSA, and NAP-2. CXCR2 Protein, Mouse (Cell-Free, His) is the recombinant mouse-derived CXCR2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

HY-P700536

	CXCR2 Protein, Human (His-SUMO) C-X-C motif chemokine receptor 2; IL8RB, interleukin 8 receptor, beta; C-X-C chemokine receptor type 2; CD182; CMKAR2;	Human	E. coli
	CXCR2, the receptor for interleukin-8 (IL-8), orchestrates neutrophil activation through a G-protein-mediated phosphatidylinositol-calcium second messenger system upon IL-8 binding. Exhibiting high-affinity binding to IL-8, CXCR2 also interacts with other ligands like CXCL3, GRO/MGSA, and NAP-2. The involvement of GNAI2 underscores the intricate signaling mechanisms regulating neutrophil function through CXCR2. CXCR2 Protein, Human (His-SUMO) is the recombinant human-derived CXCR2 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W701397

Nicotinamide N-oxide-d4
Nicotinamide N-oxide-d₄ is the deuterium labeled Nicotinamide N-oxide (HY-101407). Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.

Host:	Mouse (1) Rabbit (1)
Reactivity:	Human (2)
Application:	IHC-P (2) ICC/IF (1) WB (1) FC (1) ELISA (2)
Isotype:	IgG (1) IgG1 (1)
Conjugation:	Non-conjugated (2)
Clonality:	Polyclonal (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84207A

	CXCR2 Antibody (YA3904)(PBS only) CXCR2; IL8R2; IL8RA; IL8RB; CMKAR2; CDw128b	IHC-P, ICC/IF, FC, ELISA	Human
	CXCR2 Antibody (YA3904) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CXCR2.

HY-P81158

	CXCR2 Antibody CXC-chemokine receptor 2; CD 182; CD182; CD182 antigen; CDw128b; Chemokine (CXC) receptor 2; CMKAR2; CXCR 2; CXC R2; CXC-R2; CXCR2_HUMAN; C-X-C chemokine receptor type 2; CXCR-2; GRO/MGSA receptor; High affinity interleukin-8 receptor B; IL-8R B; IL-8 receptor type 2.	WB, IHC-P, ELISA	Human
	CXCR2 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CXCR2.